Data Insights

AB-598 by Arcus Biosciences for Ovarian Cancer: Likelihood of Approval

AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AB-598 in Ovarian Cancer

Data Insights

AB-598 by Arcus Biosciences for Cervical Cancer: Likelihood of Approval

AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AB-598 in Cervical Cancer

Data Insights

AB-598 by Arcus Biosciences for Gastric Cancer: Likelihood of Approval

AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AB-598 in Gastric Cancer

Data Insights

AB-598 by Arcus Biosciences for Bladder Cancer: Likelihood of Approval

AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AB-598 in Bladder Cancer

Data Insights

AB-598 by Arcus Biosciences for Renal Cell Carcinoma: Likelihood of Approval

AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AB-598 in Renal Cell Carcinoma

Data Insights

AB-598 by Arcus Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval

AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - AB-598 in Non-Small Cell Lung Cancer

Data Insights

AB-598 by Arcus Biosciences for Esophageal Cancer: Likelihood of Approval

AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AB-598 in Esophageal Cancer

Data Insights

AB-598 by Arcus Biosciences for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - AB-598 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

AB-598 by Arcus Biosciences for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - AB-598 in Triple-Negative Breast Cancer (TNBC)

Data Insights

AB-598 by Arcus Biosciences for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - AB-598 in Head And Neck Squamous Cell Carcinoma (HNSC)